The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

This study is testing whether a new PET scan imaging agent called 68Ga-grazytracer can track how well immunotherapy is working in patients with pancreatic cancer, helping doctors monitor treatment response more accurately. **You may be eligible if...** - You have been diagnosed with pancreatic cancer confirmed by tissue analysis - Your doctor has determined you need combination immunotherapy based on clinical guidelines - You are between 18 and 75 years old - You are in reasonably good health with an expected survival of more than 6 months **You may NOT be eligible if...** - You have serious medical conditions such as severe heart or lung failure, severe bone marrow suppression, or severe liver or kidney problems - You have a bowel perforation or complete bowel obstruction - You are pregnant, breastfeeding, or may become pregnant - You are unlikely to comply with the study procedures Talk to your doctor to see if this trial is right for you.